Share Price and Basic Stock Data
Last Updated: December 11, 2025, 9:14 pm
| PEG Ratio | 102.54 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Neogen Chemicals Ltd operates in the specialty chemicals sector, focusing on manufacturing advanced intermediates and specialty chemicals. As of March 2025, the company reported a revenue of ₹774 Cr, reflecting a steady growth trajectory from ₹686 Cr in the previous fiscal year. This trend indicates a compound annual growth rate (CAGR) of approximately 12.8% since FY 2022. However, revenue performance has shown some fluctuations in recent quarters, with a notable drop to ₹168 Cr in September 2023, before recovering to ₹210 Cr in March 2024. This volatility raises questions about demand stability and production capacity in a competitive market. Despite these fluctuations, Neogen’s ability to maintain a market cap of ₹2,604 Cr suggests a solid position within the industry, albeit with a price-to-earnings (P/E) ratio of 52.7, which may appear elevated compared to peers, hinting at market optimism or overvaluation concerns.
Profitability and Efficiency Metrics
Neogen’s profitability metrics present a mixed picture. The operating profit margin (OPM) stood at 19% for FY 2025, showcasing a recovery from a low of 16% in FY 2023. This improvement signals effective cost management amid fluctuating sales figures. However, net profit margins have declined to 4.45% in FY 2025 from 7.26% in FY 2023, primarily due to higher interest expenses, which increased to ₹51 Cr. The interest coverage ratio (ICR) of 2.89x indicates that the company is comfortably managing its interest obligations, but the rising debt levels—₹776 Cr in borrowings—could pose a risk if sales do not stabilize. Additionally, the return on capital employed (ROCE) dipped to 11.09%, reflecting the challenges in generating returns on the capital invested. Investors should watch how Neogen balances growth with profitability in the coming quarters.
Balance Sheet Strength and Financial Ratios
Neogen’s balance sheet reveals a mix of strengths and vulnerabilities. The company reported reserves of ₹803 Cr, which provide a buffer against operational uncertainties. However, the total liabilities have surged to ₹1,621 Cr, driven by increasing borrowings, which could raise concerns regarding financial leverage. The debt-to-equity ratio of 0.71x indicates a reliance on debt financing, which could be a double-edged sword, particularly in a rising interest rate environment. Furthermore, Neogen’s current ratio of 1.36x suggests a reasonable liquidity position, but the quick ratio of 0.94x indicates potential challenges in meeting short-term liabilities without liquidating inventory. Investors should carefully evaluate these financial ratios to gauge the company’s resilience against market fluctuations and economic headwinds.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Neogen Chemicals reflects a diverse mix of institutional and retail investors. Promoters hold 51.22% of the company, a decrease from 60.19% in December 2022, which may signal a dilution of control or a strategic move to enhance liquidity. Foreign institutional investors (FIIs) and domestic institutional investors (DIIs) together account for approximately 30.37%, indicating a healthy level of institutional interest. However, the public shareholding has remained relatively stable at around 18.40%. This distribution suggests a balanced investor base, which can be positive for stability. The slight decline in promoter holding could raise questions about their confidence in the company’s future, but the increased DII stake to 25.22% reflects confidence from domestic institutions, providing a counterbalance to any concerns about promoter dilution.
Outlook, Risks, and Final Insight
Looking ahead, Neogen Chemicals faces both opportunities and challenges. The specialty chemicals sector is poised for growth, driven by increasing demand for advanced materials and sustainability initiatives. However, the company must navigate risks associated with operational volatility and rising interest costs. The fluctuations in quarterly revenues and declining profit margins could impact investor sentiment. Moreover, as the company grapples with a significant debt load, future performance could hinge on effective cost management and strategic growth initiatives. Investors might consider watching for signs of improved sales stability and operational efficiency, as these will be critical for restoring confidence and enhancing shareholder value. Overall, while Neogen Chemicals presents intriguing prospects, vigilance is warranted given the underlying financial dynamics and market conditions.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Neogen Chemicals Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| HP Adhesives Ltd | 391 Cr. | 42.7 | 83.5/41.2 | 24.3 | 20.5 | 0.94 % | 13.6 % | 9.82 % | 2.00 |
| Haryana Leather Chemicals Ltd | 30.9 Cr. | 63.0 | 99.5/56.0 | 14.8 | 89.6 | 1.59 % | 8.02 % | 5.45 % | 10.0 |
| Hardcastle & Waud Mfg Co Ltd | 43.5 Cr. | 640 | 960/600 | 20.1 | 697 | 0.00 % | 6.31 % | 2.91 % | 10.0 |
| Grauer & Weil (India) Ltd | 3,500 Cr. | 77.2 | 111/74.5 | 23.2 | 22.0 | 0.65 % | 23.3 % | 17.6 % | 1.00 |
| DMCC Speciality Chemicals Ltd | 661 Cr. | 265 | 453/241 | 23.8 | 93.8 | 0.94 % | 14.1 % | 9.97 % | 10.0 |
| Industry Average | 12,766.52 Cr | 722.75 | 65.25 | 183.02 | 0.45% | 12.99% | 25.41% | 6.41 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 148 | 148 | 186 | 204 | 170 | 168 | 164 | 210 | 176 | 193 | 200 | 204 | 185 |
| Expenses | 123 | 124 | 156 | 171 | 141 | 142 | 143 | 172 | 145 | 157 | 163 | 163 | 150 |
| Operating Profit | 25 | 24 | 30 | 33 | 29 | 26 | 22 | 38 | 32 | 36 | 38 | 41 | 35 |
| OPM % | 17% | 16% | 16% | 16% | 17% | 16% | 13% | 18% | 18% | 19% | 19% | 20% | 19% |
| Other Income | 1 | 0 | 1 | 2 | 2 | 2 | 2 | 3 | 3 | 2 | 2 | -11 | 3 |
| Interest | 6 | 7 | 7 | 9 | 11 | 11 | 11 | 10 | 10 | 12 | 13 | 16 | 14 |
| Depreciation | 4 | 4 | 4 | 4 | 5 | 5 | 6 | 6 | 6 | 7 | 7 | 6 | 5 |
| Profit before tax | 16 | 14 | 21 | 21 | 16 | 12 | 7 | 25 | 19 | 20 | 20 | 8 | 19 |
| Tax % | 29% | 29% | 29% | 31% | 28% | 26% | 69% | 24% | 26% | 25% | 28% | 33% | 25% |
| Net Profit | 11 | 10 | 15 | 14 | 11 | 9 | 2 | 19 | 14 | 15 | 14 | 5 | 14 |
| EPS in Rs | 4.46 | 3.97 | 5.90 | 5.75 | 4.58 | 3.66 | 0.85 | 7.30 | 5.28 | 5.63 | 5.46 | 1.97 | 5.39 |
Last Updated: August 20, 2025, 6:15 am
Below is a detailed analysis of the quarterly data for Neogen Chemicals Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 185.00 Cr.. The value appears to be declining and may need further review. It has decreased from 204.00 Cr. (Mar 2025) to 185.00 Cr., marking a decrease of 19.00 Cr..
- For Expenses, as of Jun 2025, the value is 150.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 163.00 Cr. (Mar 2025) to 150.00 Cr., marking a decrease of 13.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 35.00 Cr.. The value appears to be declining and may need further review. It has decreased from 41.00 Cr. (Mar 2025) to 35.00 Cr., marking a decrease of 6.00 Cr..
- For OPM %, as of Jun 2025, the value is 19.00%. The value appears to be declining and may need further review. It has decreased from 20.00% (Mar 2025) to 19.00%, marking a decrease of 1.00%.
- For Other Income, as of Jun 2025, the value is 3.00 Cr.. The value appears strong and on an upward trend. It has increased from -11.00 Cr. (Mar 2025) to 3.00 Cr., marking an increase of 14.00 Cr..
- For Interest, as of Jun 2025, the value is 14.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 16.00 Cr. (Mar 2025) to 14.00 Cr., marking a decrease of 2.00 Cr..
- For Depreciation, as of Jun 2025, the value is 5.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 6.00 Cr. (Mar 2025) to 5.00 Cr., marking a decrease of 1.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 19.00 Cr.. The value appears strong and on an upward trend. It has increased from 8.00 Cr. (Mar 2025) to 19.00 Cr., marking an increase of 11.00 Cr..
- For Tax %, as of Jun 2025, the value is 25.00%. The value appears to be improving (decreasing) as expected. It has decreased from 33.00% (Mar 2025) to 25.00%, marking a decrease of 8.00%.
- For Net Profit, as of Jun 2025, the value is 14.00 Cr.. The value appears strong and on an upward trend. It has increased from 5.00 Cr. (Mar 2025) to 14.00 Cr., marking an increase of 9.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 5.39. The value appears strong and on an upward trend. It has increased from 1.97 (Mar 2025) to 5.39, marking an increase of 3.42.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 4:46 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 74 | 84 | 100 | 110 | 161 | 239 | 306 | 336 | 487 | 686 | 701 | 774 | 782 |
| Expenses | 62 | 71 | 86 | 90 | 132 | 196 | 248 | 272 | 401 | 575 | 585 | 627 | 632 |
| Operating Profit | 11 | 13 | 14 | 20 | 29 | 43 | 58 | 64 | 87 | 112 | 116 | 147 | 150 |
| OPM % | 16% | 15% | 14% | 18% | 18% | 18% | 19% | 19% | 18% | 16% | 17% | 19% | 19% |
| Other Income | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 5 | 8 | -4 | -3 |
| Interest | 5 | 5 | 5 | 8 | 10 | 12 | 12 | 14 | 19 | 29 | 42 | 51 | 56 |
| Depreciation | 1 | 1 | 1 | 1 | 2 | 3 | 5 | 7 | 12 | 16 | 23 | 26 | 24 |
| Profit before tax | 6 | 8 | 8 | 12 | 18 | 29 | 41 | 44 | 57 | 71 | 59 | 66 | 67 |
| Tax % | 41% | 37% | 39% | 33% | 39% | 28% | 30% | 29% | 22% | 30% | 31% | 27% | |
| Net Profit | 4 | 5 | 5 | 8 | 11 | 21 | 29 | 31 | 45 | 50 | 41 | 48 | 49 |
| EPS in Rs | 8.09 | 11.31 | 2.59 | 3.88 | 5.34 | 10.48 | 12.33 | 13.47 | 17.93 | 20.07 | 15.59 | 18.35 | 18.45 |
| Dividend Payout % | 25% | 18% | 77% | 26% | 19% | 14% | 16% | 17% | 15% | 15% | 13% | 5% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 25.00% | 0.00% | 60.00% | 37.50% | 90.91% | 38.10% | 6.90% | 45.16% | 11.11% | -18.00% | 17.07% |
| Change in YoY Net Profit Growth (%) | 0.00% | -25.00% | 60.00% | -22.50% | 53.41% | -52.81% | -31.20% | 38.26% | -34.05% | -29.11% | 35.07% |
Neogen Chemicals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 25% |
| 5 Years: | 20% |
| 3 Years: | 17% |
| TTM: | 9% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 28% |
| 5 Years: | 15% |
| 3 Years: | 9% |
| TTM: | 23% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 16% |
| 3 Years: | -1% |
| 1 Year: | -1% |
| Return on Equity | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 10% |
| 3 Years: | 8% |
| Last Year: | 7% |
Last Updated: September 5, 2025, 11:40 am
Balance Sheet
Last Updated: December 4, 2025, 1:43 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4 | 4 | 20 | 20 | 20 | 20 | 23 | 23 | 25 | 25 | 26 | 26 | 26 |
| Reserves | 15 | 19 | 8 | 22 | 31 | 50 | 133 | 160 | 414 | 458 | 740 | 782 | 803 |
| Borrowings | 25 | 24 | 26 | 69 | 82 | 120 | 137 | 222 | 229 | 370 | 409 | 474 | 776 |
| Other Liabilities | 18 | 21 | 27 | 41 | 48 | 56 | 61 | 87 | 131 | 202 | 230 | 338 | 344 |
| Total Liabilities | 63 | 69 | 80 | 152 | 181 | 247 | 355 | 492 | 800 | 1,054 | 1,405 | 1,621 | 1,949 |
| Fixed Assets | 14 | 13 | 17 | 56 | 67 | 83 | 111 | 127 | 285 | 347 | 361 | 228 | 251 |
| CWIP | 0 | 0 | 1 | 1 | 1 | 0 | 3 | 115 | 11 | 36 | 56 | 28 | 54 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 81 | 77 | 5 | 193 | 400 |
| Other Assets | 49 | 55 | 62 | 94 | 112 | 163 | 242 | 250 | 423 | 594 | 983 | 1,173 | 1,244 |
| Total Assets | 63 | 69 | 80 | 152 | 181 | 247 | 355 | 492 | 800 | 1,054 | 1,405 | 1,621 | 1,949 |
Below is a detailed analysis of the balance sheet data for Neogen Chemicals Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 26.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 26.00 Cr..
- For Reserves, as of Sep 2025, the value is 803.00 Cr.. The value appears strong and on an upward trend. It has increased from 782.00 Cr. (Mar 2025) to 803.00 Cr., marking an increase of 21.00 Cr..
- For Borrowings, as of Sep 2025, the value is 776.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 474.00 Cr. (Mar 2025) to 776.00 Cr., marking an increase of 302.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 344.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 338.00 Cr. (Mar 2025) to 344.00 Cr., marking an increase of 6.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 1,949.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,621.00 Cr. (Mar 2025) to 1,949.00 Cr., marking an increase of 328.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 251.00 Cr.. The value appears strong and on an upward trend. It has increased from 228.00 Cr. (Mar 2025) to 251.00 Cr., marking an increase of 23.00 Cr..
- For CWIP, as of Sep 2025, the value is 54.00 Cr.. The value appears strong and on an upward trend. It has increased from 28.00 Cr. (Mar 2025) to 54.00 Cr., marking an increase of 26.00 Cr..
- For Investments, as of Sep 2025, the value is 400.00 Cr.. The value appears strong and on an upward trend. It has increased from 193.00 Cr. (Mar 2025) to 400.00 Cr., marking an increase of 207.00 Cr..
- For Other Assets, as of Sep 2025, the value is 1,244.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,173.00 Cr. (Mar 2025) to 1,244.00 Cr., marking an increase of 71.00 Cr..
- For Total Assets, as of Sep 2025, the value is 1,949.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,621.00 Cr. (Mar 2025) to 1,949.00 Cr., marking an increase of 328.00 Cr..
Notably, the Reserves (803.00 Cr.) exceed the Borrowings (776.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -14.00 | -11.00 | -12.00 | -49.00 | -53.00 | -77.00 | -79.00 | -158.00 | -142.00 | -258.00 | -293.00 | -327.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 82 | 78 | 58 | 107 | 94 | 93 | 90 | 85 | 82 | 94 | 147 | 94 |
| Inventory Days | 173 | 178 | 190 | 228 | 192 | 188 | 257 | 211 | 258 | 275 | 353 | 265 |
| Days Payable | 117 | 120 | 130 | 177 | 141 | 111 | 71 | 122 | 131 | 147 | 134 | 220 |
| Cash Conversion Cycle | 138 | 136 | 117 | 158 | 145 | 169 | 276 | 174 | 209 | 223 | 366 | 138 |
| Working Capital Days | 140 | 140 | 126 | 67 | 49 | 63 | 96 | 67 | 111 | 80 | 190 | 169 |
| ROCE % | 26% | 27% | 26% | 23% | 23% | 26% | 22% | 17% | 14% | 13% | 10% | 11% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| SBI Contra Fund | 1,248,272 | 0.37 | 180.08 | 808,141 | 2025-12-07 15:45:16 | 54.46% |
| Axis Small Cap Fund | 1,217,809 | 0.65 | 175.68 | 1,217,809 | 2025-04-22 17:25:25 | 0% |
| SBI Large & Midcap Fund | 935,051 | 0.38 | 134.89 | 935,051 | 2025-04-22 15:56:55 | 0% |
| Aditya Birla Sun Life Small Cap Fund | 311,723 | 0.88 | 44.97 | N/A | N/A | N/A |
| Sundaram Small Cap Fund | 243,156 | 1 | 35.08 | 265,529 | 2025-12-08 07:53:01 | -8.43% |
| Invesco India Smallcap Fund | 222,523 | 0.37 | 32.1 | N/A | N/A | N/A |
| Axis Flexi Cap Fund | 212,801 | 0.23 | 30.7 | 212,801 | 2025-04-22 15:56:55 | 0% |
| SBI Equity Savings Fund | 212,711 | 0.51 | 30.69 | 212,711 | 2025-04-22 17:25:25 | 0% |
| SBI Comma Fund | 152,080 | 2.65 | 21.94 | N/A | N/A | N/A |
| ITI Small Cap Fund | 135,591 | 0.69 | 19.56 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 13.20 | 13.96 | 20.03 | 18.70 | 13.45 |
| Diluted EPS (Rs.) | 13.20 | 13.96 | 20.03 | 18.70 | 13.45 |
| Cash EPS (Rs.) | 23.66 | 22.11 | 26.49 | 22.58 | 16.38 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 299.24 | 288.21 | 193.47 | 176.12 | 78.43 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 299.24 | 288.21 | 193.47 | 176.12 | 78.43 |
| Revenue From Operations / Share (Rs.) | 294.75 | 261.82 | 275.13 | 195.37 | 144.17 |
| PBDIT / Share (Rs.) | 53.20 | 44.55 | 46.54 | 35.22 | 27.81 |
| PBIT / Share (Rs.) | 42.66 | 35.88 | 40.04 | 30.53 | 24.85 |
| PBT / Share (Rs.) | 18.94 | 19.93 | 28.44 | 22.88 | 18.95 |
| Net Profit / Share (Rs.) | 13.13 | 13.45 | 20.00 | 17.89 | 13.43 |
| NP After MI And SOA / Share (Rs.) | 13.20 | 13.51 | 20.04 | 17.89 | 13.43 |
| PBDIT Margin (%) | 18.04 | 17.01 | 16.91 | 18.02 | 19.28 |
| PBIT Margin (%) | 14.47 | 13.70 | 14.55 | 15.62 | 17.23 |
| PBT Margin (%) | 6.42 | 7.61 | 10.33 | 11.71 | 13.14 |
| Net Profit Margin (%) | 4.45 | 5.13 | 7.26 | 9.15 | 9.31 |
| NP After MI And SOA Margin (%) | 4.47 | 5.16 | 7.28 | 9.15 | 9.31 |
| Return on Networth / Equity (%) | 4.41 | 4.68 | 10.35 | 10.16 | 17.11 |
| Return on Capital Employeed (%) | 11.09 | 10.12 | 15.50 | 13.10 | 18.23 |
| Return On Assets (%) | 1.99 | 2.43 | 4.74 | 5.58 | 6.36 |
| Long Term Debt / Equity (X) | 0.21 | 0.16 | 0.26 | 0.27 | 0.63 |
| Total Debt / Equity (X) | 0.71 | 0.51 | 0.75 | 0.45 | 1.10 |
| Asset Turnover Ratio (%) | 0.48 | 0.54 | 0.74 | 0.75 | 0.79 |
| Current Ratio (X) | 1.36 | 1.49 | 1.60 | 2.26 | 1.38 |
| Quick Ratio (X) | 0.94 | 0.76 | 0.88 | 1.37 | 0.72 |
| Inventory Turnover Ratio (X) | 1.46 | 1.41 | 1.99 | 2.23 | 1.48 |
| Dividend Payout Ratio (NP) (%) | 0.00 | 20.98 | 13.72 | 11.76 | 14.89 |
| Dividend Payout Ratio (CP) (%) | 0.00 | 12.78 | 10.36 | 9.32 | 12.20 |
| Earning Retention Ratio (%) | 0.00 | 79.02 | 86.28 | 88.24 | 85.11 |
| Cash Earning Retention Ratio (%) | 0.00 | 87.22 | 89.64 | 90.68 | 87.80 |
| Interest Coverage Ratio (X) | 2.89 | 2.79 | 4.01 | 4.60 | 4.71 |
| Interest Coverage Ratio (Post Tax) (X) | 2.00 | 1.84 | 2.72 | 3.34 | 3.28 |
| Enterprise Value (Cr.) | 4637.05 | 3527.65 | 3541.31 | 4504.16 | 2217.48 |
| EV / Net Operating Revenue (X) | 5.96 | 5.11 | 5.16 | 9.24 | 6.59 |
| EV / EBITDA (X) | 33.04 | 30.02 | 30.51 | 51.28 | 34.18 |
| MarketCap / Net Operating Revenue (X) | 5.24 | 4.56 | 4.66 | 8.93 | 5.99 |
| Retention Ratios (%) | 0.00 | 79.01 | 86.27 | 88.23 | 85.10 |
| Price / BV (X) | 5.16 | 4.14 | 6.63 | 9.91 | 11.02 |
| Price / Net Operating Revenue (X) | 5.24 | 4.56 | 4.66 | 8.93 | 6.00 |
| EarningsYield | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
After reviewing the key financial ratios for Neogen Chemicals Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 13.20. This value is within the healthy range. It has decreased from 13.96 (Mar 24) to 13.20, marking a decrease of 0.76.
- For Diluted EPS (Rs.), as of Mar 25, the value is 13.20. This value is within the healthy range. It has decreased from 13.96 (Mar 24) to 13.20, marking a decrease of 0.76.
- For Cash EPS (Rs.), as of Mar 25, the value is 23.66. This value is within the healthy range. It has increased from 22.11 (Mar 24) to 23.66, marking an increase of 1.55.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 299.24. It has increased from 288.21 (Mar 24) to 299.24, marking an increase of 11.03.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 299.24. It has increased from 288.21 (Mar 24) to 299.24, marking an increase of 11.03.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 294.75. It has increased from 261.82 (Mar 24) to 294.75, marking an increase of 32.93.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 53.20. This value is within the healthy range. It has increased from 44.55 (Mar 24) to 53.20, marking an increase of 8.65.
- For PBIT / Share (Rs.), as of Mar 25, the value is 42.66. This value is within the healthy range. It has increased from 35.88 (Mar 24) to 42.66, marking an increase of 6.78.
- For PBT / Share (Rs.), as of Mar 25, the value is 18.94. This value is within the healthy range. It has decreased from 19.93 (Mar 24) to 18.94, marking a decrease of 0.99.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 13.13. This value is within the healthy range. It has decreased from 13.45 (Mar 24) to 13.13, marking a decrease of 0.32.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 13.20. This value is within the healthy range. It has decreased from 13.51 (Mar 24) to 13.20, marking a decrease of 0.31.
- For PBDIT Margin (%), as of Mar 25, the value is 18.04. This value is within the healthy range. It has increased from 17.01 (Mar 24) to 18.04, marking an increase of 1.03.
- For PBIT Margin (%), as of Mar 25, the value is 14.47. This value is within the healthy range. It has increased from 13.70 (Mar 24) to 14.47, marking an increase of 0.77.
- For PBT Margin (%), as of Mar 25, the value is 6.42. This value is below the healthy minimum of 10. It has decreased from 7.61 (Mar 24) to 6.42, marking a decrease of 1.19.
- For Net Profit Margin (%), as of Mar 25, the value is 4.45. This value is below the healthy minimum of 5. It has decreased from 5.13 (Mar 24) to 4.45, marking a decrease of 0.68.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 4.47. This value is below the healthy minimum of 8. It has decreased from 5.16 (Mar 24) to 4.47, marking a decrease of 0.69.
- For Return on Networth / Equity (%), as of Mar 25, the value is 4.41. This value is below the healthy minimum of 15. It has decreased from 4.68 (Mar 24) to 4.41, marking a decrease of 0.27.
- For Return on Capital Employeed (%), as of Mar 25, the value is 11.09. This value is within the healthy range. It has increased from 10.12 (Mar 24) to 11.09, marking an increase of 0.97.
- For Return On Assets (%), as of Mar 25, the value is 1.99. This value is below the healthy minimum of 5. It has decreased from 2.43 (Mar 24) to 1.99, marking a decrease of 0.44.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.21. This value is within the healthy range. It has increased from 0.16 (Mar 24) to 0.21, marking an increase of 0.05.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.71. This value is within the healthy range. It has increased from 0.51 (Mar 24) to 0.71, marking an increase of 0.20.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.48. It has decreased from 0.54 (Mar 24) to 0.48, marking a decrease of 0.06.
- For Current Ratio (X), as of Mar 25, the value is 1.36. This value is below the healthy minimum of 1.5. It has decreased from 1.49 (Mar 24) to 1.36, marking a decrease of 0.13.
- For Quick Ratio (X), as of Mar 25, the value is 0.94. This value is below the healthy minimum of 1. It has increased from 0.76 (Mar 24) to 0.94, marking an increase of 0.18.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 1.46. This value is below the healthy minimum of 4. It has increased from 1.41 (Mar 24) to 1.46, marking an increase of 0.05.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 20.98 (Mar 24) to 0.00, marking a decrease of 20.98.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 12.78 (Mar 24) to 0.00, marking a decrease of 12.78.
- For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 79.02 (Mar 24) to 0.00, marking a decrease of 79.02.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 87.22 (Mar 24) to 0.00, marking a decrease of 87.22.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 2.89. This value is below the healthy minimum of 3. It has increased from 2.79 (Mar 24) to 2.89, marking an increase of 0.10.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 2.00. This value is below the healthy minimum of 3. It has increased from 1.84 (Mar 24) to 2.00, marking an increase of 0.16.
- For Enterprise Value (Cr.), as of Mar 25, the value is 4,637.05. It has increased from 3,527.65 (Mar 24) to 4,637.05, marking an increase of 1,109.40.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 5.96. This value exceeds the healthy maximum of 3. It has increased from 5.11 (Mar 24) to 5.96, marking an increase of 0.85.
- For EV / EBITDA (X), as of Mar 25, the value is 33.04. This value exceeds the healthy maximum of 15. It has increased from 30.02 (Mar 24) to 33.04, marking an increase of 3.02.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 5.24. This value exceeds the healthy maximum of 3. It has increased from 4.56 (Mar 24) to 5.24, marking an increase of 0.68.
- For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. It has decreased from 79.01 (Mar 24) to 0.00, marking a decrease of 79.01.
- For Price / BV (X), as of Mar 25, the value is 5.16. This value exceeds the healthy maximum of 3. It has increased from 4.14 (Mar 24) to 5.16, marking an increase of 1.02.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 5.24. This value exceeds the healthy maximum of 3. It has increased from 4.56 (Mar 24) to 5.24, marking an increase of 0.68.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Neogen Chemicals Ltd:
- Net Profit Margin: 4.45%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 11.09% (Industry Average ROCE: 12.99%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 4.41% (Industry Average ROE: 24.61%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 2
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.94
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 58.8 (Industry average Stock P/E: 57.09)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.71
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 4.45%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Chemicals - Speciality - Others | No. 1002, 10th Floor, Thane Maharashtra 400601 | investor@neogenchem.com http://www.neogenchem.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Haridas Kanani | Chairman & Managing Director |
| Dr. Harin Kanani | Managing Director |
| Mr. Shyamsunder Upadhyay | Whole Time Director |
| Mr. Anurag Surana | Non Exe.Non Ind.Director |
| Mr. Sanjay Mehta | Independent Director |
| Mr. Hitesh Reshamwala | Independent Director |
| Prof. Ranjan Kumar Malik | Independent Director |
| Mrs. Avi Sabavala | Independent Director |
FAQ
What is the intrinsic value of Neogen Chemicals Ltd?
Neogen Chemicals Ltd's intrinsic value (as of 11 December 2025) is 1088.09 which is 1.17% lower the current market price of 1,101.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 2,907 Cr. market cap, FY2025-2026 high/low of 2,304/967, reserves of ₹803 Cr, and liabilities of 1,949 Cr.
What is the Market Cap of Neogen Chemicals Ltd?
The Market Cap of Neogen Chemicals Ltd is 2,907 Cr..
What is the current Stock Price of Neogen Chemicals Ltd as on 11 December 2025?
The current stock price of Neogen Chemicals Ltd as on 11 December 2025 is 1,101.
What is the High / Low of Neogen Chemicals Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Neogen Chemicals Ltd stocks is 2,304/967.
What is the Stock P/E of Neogen Chemicals Ltd?
The Stock P/E of Neogen Chemicals Ltd is 58.8.
What is the Book Value of Neogen Chemicals Ltd?
The Book Value of Neogen Chemicals Ltd is 314.
What is the Dividend Yield of Neogen Chemicals Ltd?
The Dividend Yield of Neogen Chemicals Ltd is 0.09 %.
What is the ROCE of Neogen Chemicals Ltd?
The ROCE of Neogen Chemicals Ltd is 10.7 %.
What is the ROE of Neogen Chemicals Ltd?
The ROE of Neogen Chemicals Ltd is 7.36 %.
What is the Face Value of Neogen Chemicals Ltd?
The Face Value of Neogen Chemicals Ltd is 10.0.